3C-BZ


3C-BZ, also known as 4-benzyloxy-3,5-dimethoxyamphetamine or as α-methylbenzscaline, is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine. It is the amphetamine analogue of benzscaline. The drug was first synthesized by Alexander Shulgin and described in his 1991 book PiHKAL.

Use and effects

In his book PiHKAL, Alexander Shulgin lists the dose range is listed as 25 to 200mg and the duration as 18 to 24hours. The effects of 3C-BZ have been reported to vary significantly, ranging from intensified emotions and strange dreams, to effects similar to those of other psychedelics like LSD or TMA.

Chemistry

Synthesis

3C-BZ was originally synthesized by Alexander Shulgin starting from 5-methoxyeugenol through a reaction with benzyl chloride to form the benzyloxy derivative of 5-methoxyeugenol. The obtained benzyl derivative was reacted with tetranitromethane to form 1--2-nitro-1-propene, from which 3C-BZ is obtained by reduction of the nitropropene with lithium aluminium hydride.
Another possible synthetic route would be the reaction of benzyl chloride with syringaldehyde to form 3,5-dimethoxy-4-benzyloxybenzaldehyde followed by condensation with nitroethane to form 1--2-nitro-1-propene. The obtained nitropropene can be reduced using lithium aluminium hydride, Red-Al, or an aluminium-mercury amalgam.

History

3C-BZ was first described in the scientific literature by Alexander Shulgin and colleagues by 1978.

Society and culture

Legal status

Canada

3C-BZ is a controlled substance in Canada under phenethylamine blanket-ban language.

United States

3C-BZ is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.